A phase II combination trial of lonafarnib, ritonavir and pegylated interferon lambda in hepatitis delta virus infected patients

Trial Profile

A phase II combination trial of lonafarnib, ritonavir and pegylated interferon lambda in hepatitis delta virus infected patients

Planning
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs Lonafarnib (Primary) ; Peginterferon lambda-1a (Primary) ; Ritonavir (Primary)
  • Indications Hepatitis D
  • Focus Therapeutic Use
  • Acronyms LIFT
  • Most Recent Events

    • 21 Mar 2018 According to Eiger BioPharmaceuticals media release, will be conducted within the National Institutes of Health (NIH) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and enrollment is planned for 2Q 2018.
    • 02 Sep 2016 New trial record
    • 10 Aug 2016 According to Eiger BioPharmaceuticals media release, this trial is likely to begin in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top